Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation

Yukinori Nakamura; Masafumi Matsuguma; Yoshihiro Tokunaga; Kaoru Yamamoto; Mayumi Tanaka; Yoshinori Tanaka; Toshiaki Yujiri; Yukio Tanizawa

doi:10.2169/internalmedicine.56.7808

CASE REPORTS

Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation

Yukinori Nakamura, Masafumi Matsuguma, Yoshihiro Tokunaga, Kaoru Yamamoto, Mayumi Tanaka, Yoshinori Tanaka, Toshiaki Yujiri, Yukio Tanizawa

Author information

Yukinori Nakamura
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Masafumi Matsuguma
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Yoshihiro Tokunaga
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Kaoru Yamamoto
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Mayumi Tanaka
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Yoshinori Tanaka
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Toshiaki Yujiri
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Yukio Tanizawa
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan

Keywords: Behçet's disease, acute myeloid leukemia, tacrolimus, azacitidine, allogeneic hematopoietic stem cell transplantation

JOURNAL OPEN ACCESS

2017 Volume 56 Issue 10 Pages 1199-1202

DOI https://doi.org/10.2169/internalmedicine.56.7808

Details

Abstract

The coexistence of acute myeloid leukemia (AML) with Behçet's disease (BD) is rare. The optimum treatment for AML-associated BD has not been established. We herein report a patient with BD who developed AML with myelodysplasia-related changes. Induction chemotherapy caused complete remission of the AML but worsened the BD. Thereafter, AML was treated with azacitidine. The BD was steroid-dependent. Tacrolimus was added, which improved the BD. The patient underwent allogeneic hematopoietic stem cell transplantation (HSCT) and remains in complete remission for both diseases. Allogeneic HSCT was found to be a potent therapeutic option for AML-associated BD. In addition, azacitidine and tacrolimus were shown to be a suitable bridging regimen before HSCT.

Corresponding author

Register with J-STAGE for free!